Skip to content

Alpha Cognition ACOG Deferred Tax Assets, Valuation Allowance

Deferred Tax Assets, Valuation Allowance at other companies

Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST

Other financials

Income statement

See full
Revenue$3.5M+20.7%
Gross profit$3.3M+12.7%
Operating income-$8.1M-138%
Net income-$6.5M-276%
EPS (diluted)-$0.32-191%

Balance sheet

See full
Cash & equivalents$54.3M+100,638%
Total equity$57.5M+49.2%
Total assets$69.2M+42.5%

Cash flow

See full
Operating cash flow-$11.8M-477%
CapEx$1.3K-97.9%
Free cash flow-$11.8M-460%

Valuation

See full
Market cap$157.21M+6.6%
P/S14.5×

Profitability

See full
Gross margin89.3%
Operating margin-250.1%
Net margin-232.2%
FCF margin-280.5%

Returns & leverage

See full
Return on equity-52.4%-5.3pp
Current ratio12.6×-4.5×

Where this comes from

Reported directly by Alpha Cognition in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsValuationAllowance.

The official record: Alpha Cognition’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alpha Cognition's deferred tax assets, valuation allowance.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alpha Cognition's deferred tax assets, valuation allowance?
Alpha Cognition (ACOG) reported deferred tax assets, valuation allowance of $19.89M in Q4 2025.
What is the long-term trend for Alpha Cognition's deferred tax assets, valuation allowance?
Over 2 years (2023 to 2025), Alpha Cognition's deferred tax assets, valuation allowance has grown at a 31.1% compound annual growth rate (CAGR), from $11.57M to $19.89M.